Alto Neuroscience Inc. (ANRO)
NYSE NYSE Primary 
ANRO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Alto Neuroscience, Inc. Investment
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Alto Neuroscience, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ANRO
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Encouraged To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Alto Neuroscience, Inc.(ANRO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
On Tuesday, Alto Neuroscience, Inc. ANRO revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
5 Stocks Under $10 Growing 50% Or More
Are you looking for low-cost stocks to add to your portfolio?
